InvestorWire NewsRoom

InvestorNewsBreak

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Q3 2026 Financial Results, Advances Pipeline Expansion Strategy
November 16, 2026

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Q3 2026 Financial Results, Advances Pipeline Expansion Strategy

CNS Pharmaceuticals (NASDAQ: CNSP), a biotechnology company focused on developing therapies for unmet medical needs, reported financial results for the third quarter ended Sept. 30, 2026, and provided an update on its pipeline expansion strategy. The company is engaged in advanced discussions with potential counterparties regarding the acquisition or licensing of therapeutic assets in neurology, oncology or rare diseases, targeting completion of its first pipeline-building transaction by year-end 2026. CNS Pharmaceuticals reported a quarterly net loss of approximately $2.5 million, or $0.24 per share, compared with a net loss of $3.2 million, or $5.76 per share, in the prior-year period.

Research and development expenses declined to approximately $0.9 million from $2.2 million a year earlier, primarily reflecting reduced clinical costs associated with Berubicin and lower TPI 287 manufacturing expenses. General and administrative expenses increased to approximately $1.8 million from $1.1 million, largely due to higher business development consulting and personnel costs. Cash and cash equivalents totaled approximately $17.2 million as of Sept. 30, 2026, compared with $7.2 million at year-end 2025, primarily reflecting proceeds from a $22.5 million private placement completed in May. The company expects its available cash resources to fund planned operations beyond the next 12 months.

To view the full press release, visit https://ibn.fm/gprDa

About CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals is a biotechnology company focused on developing innovative therapies for serious diseases. With an experienced executive team and a focus on high-value therapeutic opportunities, the Company is working to build a differentiated portfolio of assets addressing significant unmet medical needs. CNS is committed to advancing novel treatments that have the potential to improve patient outcomes while creating long-term value for patients and shareholders.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]

InvestorWire is powered by IBN

Recent NewsBreaks

NewsBreaks Categories

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(862) 930-1404

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).